What Are Cannabis Businesses Worth? Public-Market EBITDA Multiples Offer a Useful Benchmark

Following third-quarter 2026 earnings reports from Green Thumb Industries, Curaleaf and Trulieve, a familiar question comes into sharper focus for cannabis business owners, investors and prospective acquirers: What is the market willing to pay for operating earnings?

Our November 9 market snapshot indicates that the three public operators trade at markedly different enterprise-value-to-annualized-EBITDA multiples. These differences help explain how investors evaluate profitability, balance-sheet risk and future growth. They also offer useful context for private cannabis business sales, although public trading multiples should never be treated as automatic private-company asking prices.

The Big Three: Q3 2026 valuation comparison

Source: Pac Garden Assets valuation model, November 9, 2026. Share prices and calculations are from the supplied market snapshot; official closing quotations have not been independently verified. USD unless noted. Enterprise values use reported debt and cash. EBITDA is annualized by multiplying Q3 by four; figures are not trailing-twelve-month results.

What Does a 5.86x Cannabis EBITDA Multiple Actually Mean?

At 5.86x enterprise value to annualized EBITDA, investors are valuing Trulieve’s operating enterprise at approximately $5.86 for every $1 of annualized quarterly adjusted EBITDA. In an acquisition discussion, the concept is familiar: buyers commonly express business value as a multiple of sustainable annual earnings.

The critical distinction is that the public-company figure reflects a stock-market valuation, not an agreed transaction price.

Revenue multiples provide a second lens. An enterprise-value-to-revenue multiple of 2.27x means that the enterprise is valued at about $2.27 for every $1 of annualized quarterly sales. But revenue alone does not tell us whether the company is profitable, how much capital it requires, or what cash flow remains after taxes, debt service and capital expenditures.

Market capitalization and enterprise value are not interchangeable. Market cap reflects the value of shareholders’ equity. Enterprise value generally adds debt and subtracts cash to approximate the value of the operating business. For a whole-business acquisition, enterprise value is typically the more relevant starting point.

Why are the three valuations so different?

Curaleaf has the highest quarterly revenue of the group, yet its EBITDA margin is lower than those of Green Thumb and Trulieve. Nevertheless, its public enterprise value represents a materially higher multiple of annualized Q3 EBITDA. That difference may reflect expectations about future growth, geographic exposure (specifically Europe), business mix, or other risks and opportunities that are not captured by a single quarter’s earnings.

Green Thumb’s approximately 3.9x multiple and Trulieve’s approximately 5.9x multiple illustrate the same point from another direction: investors do not assign one uniform multiple to all cannabis operators. Financial performance, liquidity, debt, regulatory exposure and confidence in future earnings all influence the valuation.

Trulieve’s reported Q3 results reflect its medical operations following the deconsolidation of Harvest’s mixed medical and adult-use operations. That reporting change matters when interpreting margins and comparing historical performance. Green Thumb reports normalized EBITDA, while Curaleaf and Trulieve report adjusted EBITDA; the definitions are not identical.

Does buying below a public company’s trading multiple create value?

Potentially. A public company trading at 9x EBITDA that purchases a complementary private operator at 4x EBITDA may capture an attractive valuation spread. If the acquired earnings are durable and the integration is successful, the transaction can enhance the combined company’s economics.

But a lower acquisition multiple does not automatically make a deal accretive.

The buyer must evaluate the actual purchase price, debt and liabilities assumed, financing costs, share issuance, taxes, integration expenses, capital requirements and the timing of earnings contribution. Accretion to earnings per share, cash flow per share and intrinsic value are related but distinct tests.

In practical terms, a strategic buyer may pay more for a business with exceptional locations, management, licenses, proprietary genetics, distribution access or operational synergies. Conversely, an apparently inexpensive acquisition may require substantial capital before it can contribute reliable earnings.

What do public multiples mean for a private cannabis business sale?

For California dispensaries, cultivation facilities, manufacturers and distributors, public-company multiples are reference points rather than price lists. A single-location operation usually differs from a multi-state operator in scale, liquidity, concentration risk, governance, capital access and earnings resilience.

Sellers seeking stronger valuations at the time of sale should focus on documented sustainable EBITDA, accurate financial statements, compliant licenses, favorable lease economics, a capable management team and defensible customer or product relationships. Buyers should test whether the acquisition improves an existing operating platform, rather than simply comparing its asking multiple with a public-market headline.

Build versus buy: the lowest purchase price may not be the lowest investment

A lower asking price does not necessarily translate into a lower total investment.

A discounted cultivation facility may require major electrical upgrades, equipment replacement, environmental remediation, staffing, genetics development or months of operating losses before stabilization. Conversely, a higher-priced business with infrastructure and genetics aligned to the buyer’s end goals may require less additional capital and reach productive operations sooner. And the strategic fit may have a huge impact on the acquirer's EBITDA.

The appropriate comparison is total invested capital, including acquisition price, assumed obligations, improvements, working capital and stabilization costs, against realistic risk-adjusted returns. Strategic fit can matter as much as the headline multiple.

The takeaway for California cannabis M&A

The latest Big Three earnings illustrate why cannabis business valuation cannot be reduced to one sector-wide EBITDA multiple. Public-company trading ratios provide a useful window into investor expectations. Actual private-company transaction values depend on sustainable cash flow, quality of earnings, capital structure, strategic fit and execution risk.

Pac Garden Assets advises owners and strategic buyers on California cannabis business sales, acquisitions and real estate transactions. For a confidential discussion about an acquisition strategy or potential exit, visit https://www.pacgarden.com/contact.

FAQs

Q: What is a cannabis business EBITDA multiple?

A: It is the business or enterprise value divided by annual EBITDA, generally adjusted to reflect sustainable operations. The resulting ratio is one input in negotiating acquisition value.

Q: What is the difference between enterprise value and market capitalization?

A: Market cap is share price multiplied by economically equivalent shares outstanding. Enterprise value adds debt and other relevant claims and subtracts cash, subject to transaction-specific adjustments.

Q: Are revenue multiples useful for cannabis acquisitions?

A: Yes, as a secondary reference. Revenue alone does not capture profitability, rent burden, taxes, capital spending or the quality of earnings.

Q: Does buying below a public company’s EBITDA multiple guarantee accretion?

A: No. Financing, dilution, integration costs, tax effects and sustainable acquired cash flow determine whether the acquisition creates value.

Q: Are these multiples applicable to individual California dispensaries or cultivation facilities?

A: Not directly. Public companies have different scale, liquidity, geographic diversification and risk profiles. Private-company valuation requires asset-specific underwriting.

Editorial methodology and sources: Green Thumb Industries Q3 2026 results (Nov. 4), https://www.sec.gov/Archives/edgar/data/1795139/000119312526447207/gtbif-ex99_1.htm ; Curaleaf Q3 2026 results (Nov. 3), https://www.sec.gov/Archives/edgar/data/1756770/000162828026069455/q326-exx99xxearningsrelease.htm ; Trulieve Q3 2026 results (Nov. 5), https://investors.trulieve.com/2026-11-05-Trulieve-Reports-Third-Quarter-2026-Results . Valuation ratios from Pac Garden Assets’ November 9 working spreadsheet; confirm price timestamp, shares and EV assumptions before publication. Informational analysis only, not investment advice.